Compliance Rate

Compliance Rate 50.0%
Compliant submissions 1
Incompliant submissions 1
Total trials 2

My Organizations' Clinical Trials

Showing 1975 of 3499 entries
View as:

Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, The AXIOM Trial

Phase: N/A Priority: Normal
NCT ID: NCT05333458 Org: User:
Start: 08/29/22 End: 05/01/27 Due: 05/01/28

Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT00004547 Org: User:
Start: 01/31/00 End: 08/31/09 Due: 08/31/10

Thyroid Abnormalities Associated With Exposure to Atmospheric Emissions of Radioactive Iodine

Phase: N/A Priority: Normal
NCT ID: NCT00342693 Org: User:
Start: 02/21/06 End: 09/03/13 Due: 09/03/14

A Phase II Evaluation of Telesurgery Systems

Phase: N/A Priority: Normal
NCT ID: NCT00026923 Org: User:
Start: 01/31/99 End: 12/31/01 Due: 12/31/02

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus

Phase: N/A Priority: Normal
NCT ID: NCT01061606 Org: User:
Start: 01/31/10 End: 10/31/12 Due: 10/31/13

Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00055809 Org: User:
Start: 01/31/03 End: - Due: -

Interleukin-2 Plus Activated White Blood Cells in Treating Patients With Cancer That Has Not Responded to Chemotherapy or Radiation Therapy

Phase: N/A Priority: Normal
NCT ID: NCT00019357 Org: User:
Start: 06/30/98 End: - Due: -

A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

Phase: N/A Priority: Normal
NCT ID: NCT02621021 Org: User:
Start: 12/04/15 End: 06/16/29 Due: 06/16/30

Perioperative MVT-5873, a Fully Human Monoclonal Antibody Against a CA 19-9 Epitope, for Operable CA 19-9 Producing Pancreatic Cancers, Cholangiocarcinomas, and Metastatic Colorectal Cancers

Phase: N/A Priority: Normal
NCT ID: NCT03801915 Org: User:
Start: 11/13/19 End: 05/27/22 Due: 05/27/23

Initial Study of Gallbladder Cancer in Chile

Phase: N/A Priority: Normal
NCT ID: NCT01520259 Org: User:
Start: 01/10/12 End: - Due: -

Genetic Analysis of Psoriasis and Psoriatic Arthritis

Phase: N/A Priority: Normal
NCT ID: NCT00341809 Org: User:
Start: 07/30/04 End: 09/04/12 Due: 09/04/13

Ixabepilone in Treating Patients With Metastatic Prostate Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00087139 Org: User:
Start: 09/30/04 End: 02/28/11 Due: 02/28/12

Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00031694 Org: User:
Start: 03/31/02 End: 04/30/10 Due: 04/30/11

Treatment of Castration Resistant Prostate Cancer Using Multi-Targeted Recombinant Ad5 PSA/MUC1/Brachyury Based Immunotherapy Vaccines

Phase: N/A Priority: Normal
NCT ID: NCT03481816 Org: User:
Start: 07/24/18 End: 03/09/21 Due: 03/09/22

The New England Bladder Cancer Study

Phase: N/A Priority: Normal
NCT ID: NCT00342875 Org: User:
Start: 03/01/02 End: 07/14/20 Due: 07/14/21

Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01131234 Org: User:
Start: 05/31/10 End: 09/30/14 Due: 09/30/15

Natural History and Biology of Skin Neurofibromas in Neurofibromatosis Type 1

Phase: N/A Priority: Normal
NCT ID: NCT00314119 Org: User:
Start: 06/08/06 End: - Due: -

Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

Phase: N/A Priority: Normal
NCT ID: NCT00335764 Org: User:
Start: 04/30/06 End: 09/30/12 Due: 09/30/13

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers

Phase: N/A Priority: Normal
NCT ID: NCT05691504 Org: User:
Start: 09/14/23 End: 02/01/27 Due: 02/01/28

A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01182883 Org: User:
Start: 07/28/10 End: 04/04/12 Due: 04/04/13

Local Ablative Therapy for Treatment of Oligoprogressive, EGFR-Mutated, Non-Small Cell Lung Cancer After Treatment With Osimertinib

Phase: N/A Priority: Normal
NCT ID: NCT02759835 Org: User:
Start: 04/13/16 End: 09/20/22 Due: 09/20/23

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

Phase: N/A Priority: Normal
NCT ID: NCT02146170 Org: User:
Start: 05/28/14 End: 12/31/29 Due: 12/31/30

Alvelestat (MPH966), an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Phase: N/A Priority: Normal
NCT ID: NCT02669251 Org: User:
Start: 04/28/16 End: 12/01/27 Due: 12/01/28

Longitudinal Early Advance Care Planning Discussions and Documentation (LEADD) Program: An Exploratory Study in Adolescents and Young Adults (AYAs) Receiving Hematopoietic Stem Cell Transplant

Phase: N/A Priority: Normal
NCT ID: NCT05605574 Org: User:
Start: 11/16/22 End: 12/31/25 Due: 12/31/26

Bortezomib in Treating Children With Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT00021216 Org: User:
Start: 11/30/01 End: 12/31/05 Due: 12/31/06